Former Board Member Symbiosis II LLC Files Intent to Sell $1.29M in Clene Inc. Shares
CLNN has more than doubled off its 52-week low of $2.28.
Summary
Symbiosis II LLC, a former board member of Clene Inc., has filed a Form 144 indicating intent to sell an additional 198,890 shares, valued at approximately $1.29 million, continuing a pattern of significant share dispositions.
Key Events · Ownership and Investor Activity · CLNN
-
Proposed Share Sale
Symbiosis II LLC, a former board member, intends to sell 198,890 shares of Clene Inc. common stock, valued at approximately $1.29 million.
-
Ongoing Selling Pattern
This proposed sale follows previous sales by Symbiosis II LLC, totaling 351,110 shares for gross proceeds of over $2 million in the past three months, indicating a continued reduction of their stake.
-
Filer's Relationship
The filer, Symbiosis II LLC, is identified as a former board member, suggesting a financial decision rather than an operational one.
Analysis · CLNN · Life Sciences
This Form 144 filing indicates that Symbiosis II LLC, a former board member, intends to sell an additional $1.29 million worth of Clene Inc. shares. This continues a pattern of significant share dispositions by this entity, following over $2 million in sales in the past three months. While the company recently announced positive FDA feedback and completed a public offering, this ongoing selling pressure from a former insider could be perceived negatively by the market, especially given the company's previously disclosed "going concern" doubts. It suggests a former insider is taking liquidity, potentially capitalizing on recent positive news.
How filings like this one have moved
In the 30 days to Oct 21, 2026, 28.9% of the 1511 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.54%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CLNN was trading at $6.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $76.6M. The 52-week trading range was $2.28 to $13.50. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.